Dr. John Cush RheumNow
3 months 3 weeks ago
UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in autoimmune pts vs gen. pop. (29% vs 18%) - dx by PHQ-9, GAD-7. (OR 1.86), even after adjustments income and pain, etc. https://t.co/HoKBeAZxbS https://t.co/LnC4lqqgq7
Dr. John Cush RheumNow
3 months 3 weeks ago
Korean study 50600 adult RA pts (Dx 2010-2020) shows Sustained high-income was assoc w/ reduced mortality, esp in younger pts (adj HR 0.50 <65 years vs 0.74 ≥65 years). Amplifed by Rural residence https://t.co/DUZoNsPSHj https://t.co/PV3Umlrgvv
Dr. John Cush RheumNow
3 months 3 weeks ago
There is very little evidence that kinesio taping has any true benefits in patients with musculoskeletal disorders https://t.co/3HIJOljacA https://t.co/Xz1YvQtHGs
Dr. John Cush RheumNow
3 months 3 weeks ago
1/3 of American adults have poor sleep. New survey from Amer. Academy Sleep Medicine shows 45% of pts never discuss sleep issues with their doctors; only 15% discussed it with a sleep specialist. https://t.co/uvlHjpuVs8 https://t.co/fDOtp9rxOn
Dr. John Cush RheumNow
3 months 3 weeks ago
Update on Primary CNS Angiitis
The Journal of Neurology has posted a review and update of Primary CNS vasculitis (PCNSV), also termed primary angiitis of the CNS (PACNS). PCNSV is rare, potentially fatal, and highly treatable, making timely recognition and accurate diagnosis https://t.co/cjGX1ig8Lp
Dr. John Cush RheumNow
3 months 3 weeks ago
Open label RCT in 116 DMARD-naïve #RA pts Rx w/ tofacitinib or MTX (after 1 IM steroid injx). @3 mos, TOFA signif better than MTX for >50% SDAI improv(94 v 75%), CDAI[14.5 v 7.3), DAS28-CRP[1.7 v 1.2] https://t.co/smOuLlVFyX https://t.co/xGvbiu62OB
Dr. John Cush RheumNow
3 months 3 weeks ago
Japanese ANSWER study Rx 7268 RA pts initiating bDMARDs or JAKi by orthos or Rheums. Vs Rheums, Ortho Rx RA had longer Dz duration, more seropositivity, functional impairment, less comorbidity, more MTX/GC/TNFi, less AE D/Cs - responses & outcomes were similar https://t.co/1ryA8C2p1b
In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.
Dr. John Cush RheumNow
3 months 3 weeks ago
What's it like to have RA? MARY: "I can manage the pain, the exhaustion, and side effects of the meds. The hard part is grief. I grieve for me, the adventurer that decided what she wanted and boldly went after it, no matter what. I trusted myself to handle whatever came. Now https://t.co/GakWIy2XCt
Dr. John Cush RheumNow
3 months 3 weeks ago
TENS Efficacy in Fibromyalgia
A randomized clinical trial of transcutaneous electrical nerve stimulation (TENS) in fibromyalgia showed meaningful improvement in pain for 6 months when combined with physical therapy (PT).
https://t.co/Gm81FWoTQN https://t.co/2gq2cDFUh7
Dr. John Cush RheumNow
3 months 3 weeks ago
Brepocitinib in Dermatomyositis
The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose.
https://t.co/gYLP5artRZ https://t.co/PHYXEzzM2j
Dr. John Cush RheumNow
3 months 3 weeks ago
"When there are conflicting diagnostic possibilities, trust your excellent history and physical examination more than laboratory testing and imaging."
- Arthur Weinstein, MD
Dr. John Cush RheumNow
3 months 3 weeks ago
FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/2GkYNg1Apn https://t.co/fW2qafKCew
Dr. John Cush RheumNow
3 months 3 weeks ago
Myocarditis causes 17,000 deaths/Yr worldwide. Causes include A) iatrogenic/autoimmune: checkpoint inhibitors & gene therapy; B) High income countries: parvo B19, herpesvirus 6; C) low income: dengue, HIV, malaria and Trypanosoma cruzi (Chagas disease) https://t.co/0FjPyXygpz https://t.co/04J23AiqtK
Dr. John Cush RheumNow
3 months 3 weeks ago
Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/c9IVwQYwMN
